Profile data is unavailable for this security.
About the company
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
- Revenue in SEK (TTM)116.63m
- Net income in SEK21.19m
- Incorporated1999
- Employees36.00
- LocationGenovis ABMedicon Village, Scheelevagen 2LUND 223 63SwedenSWE
- Phone+46 46101230
- Fax+46 46128020
- Websitehttps://www.genovis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanexa AB | 10.58m | -39.06m | 607.32m | 15.00 | -- | 7.57 | -- | 57.42 | -0.2644 | -0.2644 | 0.0694 | 0.4874 | 0.0972 | 24.67 | 1.54 | 813,538.40 | -35.91 | -37.21 | -42.59 | -44.95 | 69.56 | 93.79 | -369.29 | -355.05 | 2.07 | -21.98 | 0.2165 | -- | -16.93 | 70.11 | 67.40 | -- | 21.42 | -- |
| OssDsign AB | 180.16m | -50.99m | 674.82m | 32.00 | -- | 2.18 | -- | 3.75 | -0.5493 | -0.5493 | 2.06 | 2.80 | 0.5109 | 0.3672 | 6.95 | 5,629,938.00 | -14.46 | -25.42 | -16.05 | -28.59 | 96.29 | 85.57 | -28.30 | -82.42 | 6.33 | -13.77 | 0.0044 | -- | 34.51 | 48.59 | -2.68 | -- | 24.28 | -- |
| Optomed Oyj | 181.03m | -70.32m | 677.01m | 111.00 | -- | 2.66 | -- | 3.74 | -0.3374 | -0.3374 | 0.8688 | 1.12 | 0.5363 | 2.87 | 5.07 | 154,009.00 | -20.83 | -17.19 | -25.75 | -20.69 | 63.60 | 64.81 | -38.85 | -34.21 | 2.03 | -8.91 | 0.1014 | -- | 13.67 | 5.61 | -21.83 | -- | 5.30 | -- |
| BioPorto A/S | 51.83m | -123.04m | 682.22m | 48.00 | -- | 12.56 | -- | 13.16 | -0.1973 | -0.1973 | 0.083 | 0.0774 | 0.4132 | 2.55 | 4.69 | 962,131.60 | -98.08 | -65.22 | -133.92 | -88.74 | 63.90 | 64.15 | -237.40 | -222.22 | 1.71 | -- | 0.1916 | -- | 17.07 | 6.36 | -21.15 | -- | -20.56 | -- |
| Senzime AB (publ) | 89.71m | -120.62m | 785.29m | 50.00 | -- | 2.25 | -- | 8.75 | -0.8672 | -0.8672 | 0.6394 | 2.22 | 0.234 | 1.73 | 5.99 | 1,794,120.00 | -31.47 | -35.09 | -34.04 | -37.52 | 41.86 | 8.75 | -134.46 | -400.65 | 4.30 | -7.70 | 0.0399 | -- | 63.55 | 54.18 | 11.50 | -- | 40.12 | -- |
| Omda AS | 446.11m | -28.44m | 814.93m | 260.00 | -- | 25.48 | 29.27 | 1.83 | -1.51 | -1.51 | 23.59 | 1.63 | 0.6793 | 26.59 | 21.70 | 1,772,075.00 | -4.33 | -5.14 | -5.39 | -6.63 | 93.69 | 91.09 | -6.37 | -10.32 | 0.6483 | 0.5281 | 0.9359 | -- | 3.45 | 15.80 | -163.95 | -- | -15.57 | -- |
| Nexstim Oyj | 106.58m | -3.00m | 893.74m | 40.00 | -- | 26.43 | 127.15 | 8.39 | -0.042 | -0.042 | 1.47 | 0.4426 | 0.8553 | 0.5613 | 4.66 | 251,616.80 | -2.40 | -12.40 | -4.17 | -20.76 | 94.36 | 95.09 | -2.81 | -16.29 | 1.08 | 0.7835 | 0.6002 | -- | 20.55 | 21.14 | 32.79 | -- | 15.13 | -- |
| C Rad AB | 442.00m | 10.40m | 913.09m | 110.00 | 89.41 | 2.70 | 44.11 | 2.07 | 0.3104 | 0.3104 | 13.25 | 10.28 | 0.8928 | 4.29 | 2.40 | 4,018,182.00 | 2.10 | 7.01 | 2.99 | 9.81 | 51.95 | 46.99 | 2.35 | 7.12 | 2.77 | 1.55 | 0.0264 | 2.44 | -5.78 | 14.80 | -81.40 | -6.08 | -- | -- |
| Sedana Medical AB (publ) | 197.61m | -40.65m | 1.01bn | 117.00 | -- | 1.11 | -- | 5.12 | -0.4092 | -0.4092 | 1.99 | 9.14 | 0.2012 | 1.46 | 9.47 | 2,670,406.00 | -4.14 | -4.90 | -4.34 | -5.16 | 70.47 | 68.32 | -20.57 | -30.26 | 3.28 | -21.90 | 0.0045 | -- | 16.17 | 20.06 | 82.09 | -- | 26.45 | -- |
| ADDvise Group AB (publ) | 1.62bn | 4.30m | 1.04bn | 615.00 | 19.91 | 0.9402 | 9.37 | 0.6416 | 0.0864 | 0.0864 | 3.44 | 1.83 | 0.5167 | 7.91 | 4.96 | 2,534,790.00 | 0.1399 | 3.41 | 0.174 | 4.28 | 39.91 | 46.52 | 0.2708 | 6.06 | 0.7562 | 1.62 | 0.5251 | 0.4389 | 21.68 | 36.71 | -13.04 | 85.85 | 52.63 | -- |
| Paxman AB (publ) | 295.08m | 4.92m | 1.14bn | 142.00 | 177.75 | 2.67 | 46.28 | 3.86 | 0.2757 | 0.2757 | 14.26 | 18.38 | 0.8486 | 3.45 | 4.71 | 2,810,305.00 | 1.37 | 0.8426 | 1.60 | 1.20 | 67.34 | 68.75 | 1.61 | 0.7966 | 4.07 | 1.71 | 0.0245 | 0.00 | 20.41 | 24.30 | 382.55 | 70.92 | -3.73 | -- |
| Genovis AB | 116.63m | 21.19m | 1.17bn | 36.00 | 54.89 | 4.44 | 36.28 | 10.03 | 0.3225 | 0.3225 | 1.78 | 3.99 | 0.3404 | -- | -- | 3,644,719.00 | 6.18 | 15.62 | 6.57 | 17.56 | 90.28 | 88.86 | 18.16 | 25.11 | -- | -- | 0.2171 | 0.00 | -17.62 | 16.58 | -46.48 | 28.08 | -1.42 | -- |
| BICO Group AB | 1.51bn | -1.26bn | 1.20bn | 586.00 | -- | 0.6786 | -- | 0.7988 | -17.83 | -9.68 | 21.34 | 25.67 | 0.3269 | 3.30 | 3.65 | 2,074,793.00 | -27.41 | -- | -35.79 | -- | 36.91 | -- | -83.83 | -- | 1.13 | -- | 0.4174 | -- | -3.19 | -- | 88.56 | -- | -- | -- |
| Surgical Science Sweden AB | 975.04m | 69.83m | 1.32bn | 328.00 | 18.94 | 0.3076 | 9.09 | 1.36 | 1.37 | 1.37 | 19.11 | 84.27 | 0.2051 | 1.72 | 7.09 | 3,558,537.00 | 1.47 | 3.91 | 1.55 | 4.18 | 66.61 | 68.94 | 7.16 | 21.55 | 3.44 | -- | 0.0004 | 0.00 | 0.1398 | 54.17 | -43.73 | 59.89 | 39.76 | -- |
| Nordhealth As | 532.20m | -112.78m | 1.41bn | 450.00 | -- | 3.58 | -- | 2.65 | -1.52 | -1.52 | 7.17 | 9.30 | 0.6188 | -- | 8.10 | 1,378,527.00 | -13.11 | -- | -14.99 | -- | 82.95 | -- | -21.19 | -- | -- | -- | 0.00 | -- | 24.03 | -- | 31.06 | -- | -- | -- |
| Stille AB | 552.55m | 40.41m | 1.63bn | 208.00 | 40.22 | 2.35 | 18.35 | 2.94 | 4.50 | 4.50 | 62.09 | 77.10 | 0.531 | 1.55 | 7.66 | 3,891,176.00 | 3.88 | 6.20 | 4.55 | 7.11 | 52.45 | 47.21 | 7.31 | 9.48 | 1.87 | -- | 0.00 | 16.29 | 93.27 | 29.47 | 118.44 | 20.53 | 13.88 | -- |
Data as of Feb 13 2026. Currency figures normalised to Genovis AB's reporting currency: Swedish Krona SEK
32.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Teknik Innovation Norden Fonder ABas of 31 Dec 2025 | 3.86m | 5.85% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 3.51m | 5.32% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025 | 3.44m | 5.20% |
| Andra AP-fondenas of 31 Dec 2025 | 2.73m | 4.13% |
| Aktia Bank Plc (Investment Management)as of 31 Dec 2025 | 1.97m | 2.98% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 1.87m | 2.82% |
| Nordea Investment Management AB (Finland)as of 31 Dec 2025 | 1.13m | 1.71% |
| Schroder Investment Management (Europe) SA (Finland)as of 31 Dec 2025 | 1.03m | 1.56% |
| Amundi Asset Management SASU (Investment Management)as of 31 Dec 2025 | 801.37k | 1.21% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 2025 | 800.48k | 1.21% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
